1. "Department of Medicine"
Formats
  1. Journal Article (19347)
  2. Meeting Abstract (15823)
  3. Review (1102)
  4. Book Section (924)
  5. Editorial (580)
  6. Research Letter (301)
  7. Conference Paper (299)
  8. Guidelines (285)
  9. Correspondence (226)
  10. Miscellaneous (87)
  11. Book Whole (61)
Groups
  1. Department of Medicine (39035)
  2. Solid Tumor Oncology Division (22035)
  3. Hematologic Malignancies, Division of (13004)
  4. Center for Hematologic Malignancies (10842)
  5. GSK Faculty (10530)
  6. Survivorship Research (9202)

More Groups

People
  1. Robert Motzer (1243)
  2. Howard Scher (1130)
  3. Sergio Giralt (1050)
  4. Miguel-Angel Perales (913)
  5. Clifford Hudis (905)
  6. Jedd Wolchok (905)

More People

Years
  1. 2025 (643)
  2. 2024 (2141)
  3. 2023 (2451)
  4. 2022 (2621)
  5. 2021 (2534)
  6. 2020 (2560)

More Years

Publications
  1. Journal of Clinical Oncology (6050)
  2. Blood (3572)
  3. Annals of Oncology (1395)
  4. Cancer Research (1238)
  5. Clinical Cancer Research (890)
  6. Biology of Blood and Marrow Transplantation (679)

More Publications

Publishers
  1. American Society of Clinical Oncology (6364)
  2. Elsevier Inc. (4610)
  3. American Society of Hematology (3843)
  4. American Association for Cancer Research (2879)
  5. Oxford University Press (2271)
  6. Nature Publishing Group (2080)

More Publishers

Results (39035)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Transcriptomic profiling to identify subsets of immune hot locally advanced rectal adenocarcinomas with favorable outcomes after neoadjuvant treatment
    Meeting Abstract

    Sanchez Vega, F.; Chatila, W. K.; Kim, J. K.; Walch, H. S.; Marco, M.; Chen, C. T.; Wu, F.; Khalil, D.; Ganesh, K.; Qu, X.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Phase 2 trial of immunotherapy in tumors with CDK12 inactivation (IMPACT): Results from cohort A of patients (pts) with metastatic castration resistant prostate cancer (mCRPC) receiving dual immune checkpoint inhibition (ICI)
    Meeting Abstract

    Alva, A. S.; Li, J.; Chou, J.; Reimers, M. A.; McKay, R. R.; Zhang, J.; Daignault-Newton, S.; Palmbos, P. L.; Reichert, Z. R.; Cieslik, M.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Zolbetuximab + CAPOX versus CAPOX in first-line treatment of claudin18.2(+)/HER2(-) advanced/metastatic gastric or gastroesophageal junction adenocarcinoma: GLOW phase 3 study
    Meeting Abstract

    Shah, M. A.; Ajani, J. A.; Al-Batran, S. E.; Bang, Y. J.; Catenacci, D. V. T.; Enzinger, P. C.; Ilson, D. H.; Kim, S. S.; Lordick, F.; Shitara, K.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Nivolumab (NIVO) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): Expanded efficacy, safety, and subgroup analyses from CheckMate 649
    Meeting Abstract

    Shitara, K.; Janjigian, Y. Y.; Moehler, M. H.; Garrido, M.; Gallardo, C.; Shen, L.; Yamaguchi, K.; Wyrwicz, L.; Skoczylas, T.; Bragagnoli, C. A. S.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Brain metastasis in gastroesophageal adenocarcinoma: Outcomes and molecular features
    Meeting Abstract

    Tsai, C.; Nguyen, B.; Luthra, A.; Chou, J. F.; Tang, L. H.; Strong, V. E.; Molena, D.; Jones, D. R.; Coit, D. G.; Ilson, D. H.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • A quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of patients in CheckMate 649: Nivolumab plus chemotherapy versus chemotherapy as first-line treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC)
    Meeting Abstract

    Sugarman, R.; Botteman, M.; Rusibamayila, N.; Nguyen, H.; Lin, D.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Number needed to treat (NNT) analysis of patients in CheckMate 649 (CM 649): Nivolumab plus chemotherapy versus chemotherapy as first-line (1L) treatment for advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (GC/GEJ/EAC)
    Meeting Abstract

    Sugarman, R.; Nunna, S.; Betts, K. A.; Nie, X.; Nguyen, H.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Randomized phase II trial of postoperative adjuvant capecitabine and temozolomide versus observation in high-risk pancreatic neuroendocrine tumors: SWOG S2104
    Meeting Abstract

    Soares, H. P.; Guthrie, K. A.; Ahmad, S. A.; Washington, M. K.; Ramnaraign, B. H.; Raj, N. P.; Seigel, C.; Bellasea, S.; Chiorean, E. G.; Dasari, A.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • The immune impact of PI3K-AKT pathway inhibition in colorectal cancer
    Meeting Abstract

    Nusrat, M.; Syed, M. A.; Katkhuda, R.; Parra, E. R.; Wistuba, I. I.; Kong, P.; Koehne, A.; Dasari, A.; Overman, M. J.; Menter, D.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Distinct differences in genomic profile of gastric and gastroesophageal junction adenocarcinoma
    Meeting Abstract

    Nakauchi, M.; Walch, H. S.; Chatila, W. K.; Tran, T.; Vos, E. L.; Sihag, S.; Tang, L. H.; Coit, D. G.; Stadler, Z. K.; Janjigian, Y. Y.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save